CD4 and neoplasm: Their proliferating CD4+ counterparts upregulated ENTPD1 (CD39) and ITGAE (CD103) (Figure 4A), like proliferating CD8+ T cells (Supplemental Figure 4A), and hence this mobilized population is enriched for putative tumor antigen specificity (25–27).